These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26172225)

  • 21. The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.
    Wu W; Liu S
    Curr Top Med Chem; 2017; 17(3):361-370. PubMed ID: 27572081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contemporary Anti-Ebola Drug Discovery Approaches and Platforms.
    Schneider-Futschik EK; Hoyer D; Khromykh AA; Baell JB; Marsh GA; Baker MA; Li J; Velkov T
    ACS Infect Dis; 2019 Jan; 5(1):35-48. PubMed ID: 30516045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy of Ebola hemorrhagic fever: a brief review of current status and future perspectives.
    Olszanecki R; Gawlik G
    Folia Med Cracov; 2014; 54(3):67-77. PubMed ID: 25694097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
    Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
    J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.
    Geisbert TW; Strong JE; Feldmann H
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S91-7. PubMed ID: 26063223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small molecule inhibitors of ebola virus infection.
    Picazo E; Giordanetto F
    Drug Discov Today; 2015 Feb; 20(2):277-86. PubMed ID: 25532798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improving attrition rates in Ebola virus drug discovery.
    Glisic S; Paessler S; Veljkovic N; Perovic VR; Prljic J; Veljkovic V
    Expert Opin Drug Discov; 2015; 10(9):1025-32. PubMed ID: 26125997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The year that Ebola virus took over west Africa: missed opportunities for prevention.
    Bausch DG
    Am J Trop Med Hyg; 2015 Feb; 92(2):229-232. PubMed ID: 25561568
    [No Abstract]   [Full Text] [Related]  

  • 29. State-of-the-Art Workshops on Medical Countermeasures Potentially Available for Human Use Following Accidental Exposures to Ebola Virus.
    Jahrling PB; Hensley LE; Barrett K; Lane HC; Davey RT
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S84-90. PubMed ID: 25957962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
    Oestereich L; Lüdtke A; Wurr S; Rieger T; Muñoz-Fontela C; Günther S
    Antiviral Res; 2014 May; 105():17-21. PubMed ID: 24583123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug and vaccine access in the Ebola epidemic: advising caution in compassionate use.
    Hantel A; Olopade CO
    Ann Intern Med; 2015 Jan; 162(2):141-2. PubMed ID: 25322080
    [No Abstract]   [Full Text] [Related]  

  • 32. A US Food and Drug Administration perspective on evaluating medical products for Ebola.
    Russek-Cohen E; Rubin D; Price D; Sun W; Cox E; Borio L
    Clin Trials; 2016 Feb; 13(1):105-9. PubMed ID: 26768565
    [No Abstract]   [Full Text] [Related]  

  • 33. The early clinical development of Ebola virus treatments.
    Bradfute SB
    Expert Opin Investig Drugs; 2017 Jan; 26(1):1-4. PubMed ID: 27838928
    [No Abstract]   [Full Text] [Related]  

  • 34. Comprehensive Review on Ebola (EBOV) Virus: Future Prospects.
    Khan S; Muhammad ; Rauf A; Khan A; Rizwan M; Patel S; Khan H; Mahasneh AM; Mubarak MS
    Infect Disord Drug Targets; 2018; 18(2):96-104. PubMed ID: 28820067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.
    Madelain V; Nguyen TH; Olivo A; de Lamballerie X; Guedj J; Taburet AM; Mentré F
    Clin Pharmacokinet; 2016 Aug; 55(8):907-23. PubMed ID: 26798032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling Ebola virus dynamics: Implications for therapy.
    Martyushev A; Nakaoka S; Sato K; Noda T; Iwami S
    Antiviral Res; 2016 Nov; 135():62-73. PubMed ID: 27743917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Evaluation of Ebola Virus Disease Therapeutics.
    Liu G; Wong G; Su S; Bi Y; Plummer F; Gao GF; Kobinger G; Qiu X
    Trends Mol Med; 2017 Sep; 23(9):820-830. PubMed ID: 28822631
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives towards antiviral drug discovery against Ebola virus.
    Mirza MU; Vanmeert M; Ali A; Iman K; Froeyen M; Idrees M
    J Med Virol; 2019 Dec; 91(12):2029-2048. PubMed ID: 30431654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of therapeutics for treatment of Ebola virus infection.
    Li H; Ying T; Yu F; Lu L; Jiang S
    Microbes Infect; 2015 Feb; 17(2):109-17. PubMed ID: 25498866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. INFECTIOUS DISEASE. As Ebola epidemic draws to a close, a thin scientific harvest.
    Cohen J; Enserink M
    Science; 2016 Jan; 351(6268):12-3. PubMed ID: 26721981
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.